Novartis pays US$310 million upfront for inflammation specialist IFM

Singapore News News

Novartis pays US$310 million upfront for inflammation specialist IFM
Singapore Latest News,Singapore Headlines
  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 66%

Novartis on Monday said it had agreed to pay US$310 million upfront, with the possibility for more later, for some assets of Boston-based ...

ZURICH: Novartis on Monday said it had agreed to pay US$310 million upfront, with the possibility for more later, for some assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker seeks to expand its immunology pipeline.

The deal for the IFM subsidiary IFM Tre could eventually reach nearly US$1.6 billion, IFM said in a statement, should the portfolio of clinical and preclinical molecules meet milestones. IFM has one molecule, IFM-2427, in an early Phase 1 trial, as well as other less-developed assets.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

ChannelNewsAsia /  🏆 6. in SG

Singapore Latest News, Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

US jury says Bayer must pay US$81 million to man in Roundup cancer trialUS jury says Bayer must pay US$81 million to man in Roundup cancer trialA U.S. jury on Wednesday awarded US$80.9 million to a man who claimed his use of Bayer AG's glyphosate-based weed killer Roundup caused his ...
Read more »

Fresenius Medical Care to pay US$231 million to resolve criminal, civil foreign bribery chargesGermany-based dialysis clinic operator Fresenius Medical Care AG will pay about US$231 million to resolve criminal and civil allegations that the ...
Read more »

Novartis new MS drug Mayzent to be priced at US$88,000 per yearNovartis new MS drug Mayzent to be priced at US$88,000 per yearNovartis will price its new Mayzent multiple sclerosis drug at US$88,000 dollars per year, the Swiss company's head of pharmaceuticals, Paul ...
Read more »

Bayer, J&J settle US Xarelto litigation for US$775 millionBayer, J&J settle US Xarelto litigation for US$775 millionBayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of ...
Read more »

US jury says Bayer must pay US$81m to man in Roundup cancer trialUS jury says Bayer must pay US$81m to man in Roundup cancer trialA U.S. jury on Wednesday awarded US$80.9 million to a man who claimed his use of Bayer AG's glyphosate-based weed killer Roundup caused his ...
Read more »

E-commerce firm Shopmatic buys brick-and-mortar retail solutions specialist OctopusE-commerce firm Shopmatic buys brick-and-mortar retail solutions specialist OctopusLOCAL e-commerce solutions startup Shopmatic is acquiring brick-and-mortar retail solutions specialist Octopus Retail Management as it pursues an omnichannel strategy. Read more at The Business Times.
Read more »

AstraZeneca pays up to US$6.9 billion in Daiichi Sankyo cancer dealAstraZeneca Plc and Japan's Daiichi Sankyo Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Daiichi's cancer ...
Read more »

Singapore Exchange buys 20% stake in forex trading platform for US$25 millionSingapore Exchange buys 20% stake in forex trading platform for US$25 millionSINGAPORE: Singapore Exchange, which is positioning itself as a multi-asset bourse, has acquired a 20 per cent stake in an upstart foreign ...
Read more »

Nike fined US$14 million for blocking cross-border sales of soccer merchandiseNike fined US$14 million for blocking cross-border sales of soccer merchandiseEU antitrust regulators fined U.S. sportswear maker Nike 12.5 million euros (US$14.14 million) on Monday for restricting cross-border sales of ...
Read more »



Render Time: 2025-04-08 09:18:44